Compounds > carbon tetrachloride
Page last updated: 2024-08-17

carbon tetrachloride and s 1033

carbon tetrachloride has been researched along with s 1033 in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Friedman, SL; Kwong, SQ; Lam, RWC; Li, FR; Liu, Y; Lui, ELH; Wang, Z; Ye, T; Zhang, GC; Zhang, H1
Bahabadi, M; Goudarzi, F; Hajilooi, M; Hashemnia, M; Hedayatyanfard, K; Karimi, J; Khanjarsim, V; Kheiripour, N; Khodadadi, I; Mohammadalipour, A; Sheikh, N; Solgi, G1
Goudarzi, F; Hashemnia, M; Mohammadalipour, A; Ravan, AP1

Other Studies

3 other study(ies) available for carbon tetrachloride and s 1033

ArticleYear
Inhibition of PDGF, TGF-β, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib.
    Journal of hepatology, 2011, Volume: 55, Issue:3

    Topics: Actins; Animals; Apoptosis; Bile Ducts; Carbon Tetrachloride; Cell Proliferation; Collagen; G1 Phase Cell Cycle Checkpoints; Genes, abl; Hepatic Stellate Cells; Hepatocytes; Humans; Ligation; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Platelet-Derived Growth Factor; PPAR gamma; Protein-Tyrosine Kinases; Pyrimidines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Transforming Growth Factor beta

2011
Protective effects of combined Losartan and Nilotinib on carbon tetrachloride (CCl
    Drug and chemical toxicology, 2020, Volume: 43, Issue:5

    Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Carbon Tetrachloride; Drug Therapy, Combination; Liver Cirrhosis; Losartan; Male; Oxidative Stress; Protein-Tyrosine Kinases; Pyrimidines; Rats; Rats, Wistar; Transforming Growth Factor beta1; Weight Gain

2020
Increasing the effectiveness of tyrosine kinase inhibitor (TKI) in combination with a statin in reducing liver fibrosis.
    Clinical and experimental pharmacology & physiology, 2019, Volume: 46, Issue:12

    Topics: Animals; Atorvastatin; Carbon Tetrachloride; Cells, Cultured; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Synergism; Hepatic Stellate Cells; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Liver Cirrhosis; Male; Protein Kinase Inhibitors; Pyrimidines; Rats; Rats, Wistar; Treatment Outcome

2019